Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefextinib in Relapsed or Refractory Acute Myelogenous Leukemia
NCT04187495Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nefextinib in acute myeloid leukemia (AML), sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Adverse events (AEs) at 8 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Status: unknown.
02
Drugs
nefextinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04187495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187495.